Literature DB >> 21695622

Consolidated standards of reporting trials (CONSORT) for traditional Chinese medicine: current situation and future development.

Zhaoxiang Bian1, Baoyan Liu, David Moher, Taixiang Wu, Youping Li, Hongcai Shang, Chungwah Cheng.   

Abstract

The reporting standards for randomized controlled trials were first published in 1996 by a group of scientists under the name "CONSORT," which means consolidated standards of reporting trials. Revisions followed in 2001 and 2010. A draft of the CONSORT for traditional Chinese medicine (TCM) was published in both Chinese and English in 2007. After publication of the draft, comments were solicited from the medical community. Some papers did raise concerns about which items should be included in the CONSORT for TCM such as the rationale of the trial design, intervention, outcome assessment, and adverse events. We have now reached the next step which is the finalization of the CONSORT for TCM. Three tasks remain. First, the major changes in CONSORT statement 2010 should be integrated into the CONSORT for TCM. Second, Chinese drugs from minerals and animals should be included in the guidelines. Finally, agreement must be reached among the working groups. Once the draft is finalized, wide dissemination and co-publication will be considered.

Mesh:

Year:  2011        PMID: 21695622     DOI: 10.1007/s11684-011-0132-z

Source DB:  PubMed          Journal:  Front Med        ISSN: 2095-0217            Impact factor:   4.592


  15 in total

1.  Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation.

Authors:  D Moher; A Jones; L Lepage
Journal:  JAMA       Date:  2001-04-18       Impact factor: 56.272

2.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials.

Authors:  D Moher; K F Schulz; D G Altman
Journal:  Lancet       Date:  2001-04-14       Impact factor: 79.321

3.  CONSORT 2010 Statement-unfinished update?

Authors:  Jochen W L Cals; Ludovic G P M van Amelsvoort; Daniel Kotz; Mark G Spigt
Journal:  J Clin Epidemiol       Date:  2011-01-05       Impact factor: 6.437

4.  Improving the quality of randomized controlled trials in Chinese herbal medicine, part IV: applying a revised CONSORT checklist to measure reporting quality.

Authors:  Zhao-Xiang Bian; David Moher; Simon Dagenais; You-Ping Li; Tai-Xiang Wu; Liang Liu; Jiang-Xia Miao; Lisa Song; Hui-Min Zhang
Journal:  Zhong Xi Yi Jie He Xue Bao       Date:  2006-05

5.  Improving the quality of randomized controlled trials in Chinese herbal medicine, part II: control group design.

Authors:  Zhao-Xiang Bian; David Moher; Simon Dagenais; You-Ping Li; Liang Liu; Tai-Xiang Wu; Jiang-Xia Miao
Journal:  Zhong Xi Yi Jie He Xue Bao       Date:  2006-03

6.  Precise reporting of traditional Chinese medicine interventions in randomized controlled trials.

Authors:  Zhao-xiang Bian; David Moher; You-ping Li; Tai-xiang Wu; Simon Dagenais; Chung-wah Cheng; Jing Li; Ting-qian Li
Journal:  Zhong Xi Yi Jie He Xue Bao       Date:  2008-07

7.  Appropriately selecting and concisely reporting the outcome measures of randomized controlled trials of traditional Chinese medicine.

Authors:  Zhao-xiang Bian; David Moher; You-ping Li; Tai-xiang Wu; Simon Dagenais; Chung-wah Cheng; Jing Li; Ting-qian Li
Journal:  Zhong Xi Yi Jie He Xue Bao       Date:  2008-08

8.  Transparently reporting adverse effects of traditional Chinese medicine interventions in randomized controlled trials.

Authors:  Chung-Wah Cheng; Zhao-Xiang Bian; You-Ping Li; David Moher; Tai-Xiang Wu; Simon Dagenais; Jing Li; Ting-Qian Li
Journal:  Zhong Xi Yi Jie He Xue Bao       Date:  2008-09

9.  Improving the quality of reporting of randomized controlled trials. The CONSORT statement.

Authors:  C Begg; M Cho; S Eastwood; R Horton; D Moher; I Olkin; R Pitkin; D Rennie; K F Schulz; D Simel; D F Stroup
Journal:  JAMA       Date:  1996-08-28       Impact factor: 56.272

10.  Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals.

Authors:  K F Schulz; I Chalmers; D A Grimes; D G Altman
Journal:  JAMA       Date:  1994-07-13       Impact factor: 56.272

View more
  19 in total

1.  Translating evidence into policy in China: opportunities and challenges.

Authors:  Jiyao Wang; Xuejuan Jin
Journal:  Front Med       Date:  2011-10-02       Impact factor: 4.592

Review 2.  A systematic review and meta-analysis on the use of traditional Chinese medicine compound kushen injection for bone cancer pain.

Authors:  Bao Yanju; Liping Yang; Baojin Hua; Wei Hou; Zhan Shi; Weidong Li; Conghuang Li; Cihui Chen; Rui Liu; Yinggang Qin; Wenliang Lv
Journal:  Support Care Cancer       Date:  2013-11-26       Impact factor: 3.603

Review 3.  Promoting blood circulation for removing blood stasis therapy for acute intracerebral hemorrhage: a systematic review and meta-analysis.

Authors:  Hui-qin Li; Jing-jing Wei; Wan Xia; Ji-huang Li; Ai-ju Liu; Su-bing Yin; Chen Wang; Liang Song; Yan Wang; Guo-qing Zheng; Ji-ping Fan
Journal:  Acta Pharmacol Sin       Date:  2015-05-11       Impact factor: 6.150

4.  Barriers to the registration and conduct of Cochrane systematic reviews of traditional East Asian medicine therapies.

Authors:  L Susan Wieland; Ruth Brassington; Geraldine Macdonald
Journal:  Eur J Integr Med       Date:  2019-11-10       Impact factor: 1.314

Review 5.  Beneficial effects and safety of corticosteroids combined with traditional chinese medicine for pemphigus: a systematic review.

Authors:  Tingting Zhou; Peiru Zhou; Hong Hua; Xiaosong Liu
Journal:  Evid Based Complement Alternat Med       Date:  2015-02-22       Impact factor: 2.629

Review 6.  Assessment of the reporting quality of randomized controlled trials on treatment of coronary heart disease with traditional chinese medicine from the chinese journal of integrated traditional and Western medicine: a systematic review.

Authors:  Fang-fang Fan; Qin Xu; Qi Sun; Sheng-jun Zhao; Ping Wang; Xue-rui Guo
Journal:  PLoS One       Date:  2014-01-28       Impact factor: 3.240

7.  Shengmai injection, a traditional chinese patent medicine, for intradialytic hypotension: a systematic review and meta-analysis.

Authors:  Chao-Yang Chen; Ling-Yan Lu; Peng Chen; Kang-Ting Ji; Jia-Feng Lin; Peng-Lin Yang; Ji-Fei Tang; Yan Wang
Journal:  Evid Based Complement Alternat Med       Date:  2013-02-07       Impact factor: 2.629

Review 8.  Chinese herbal medicine for aspirin resistance: a systematic review of randomized controlled trials.

Authors:  Ai-Ju Liu; Hui-Qin Li; Ji-Huang Li; Yuan-Yuan Wang; Dong Chen; Yan Wang; Guo-Qing Zheng
Journal:  Evid Based Complement Alternat Med       Date:  2014-02-20       Impact factor: 2.629

Review 9.  An overview of systematic reviews of shenmai injection for healthcare.

Authors:  Ling-Yan Lu; Guo-Qing Zheng; Yan Wang
Journal:  Evid Based Complement Alternat Med       Date:  2014-02-12       Impact factor: 2.629

Review 10.  Effectiveness guidance document (EGD) for Chinese medicine trials: a consensus document.

Authors:  Claudia M Witt; Mikel Aickin; Daniel Cherkin; Chun Tao Che; Charles Elder; Andrew Flower; Richard Hammerschlag; Jian-Ping Liu; Lixing Lao; Steve Phurrough; Cheryl Ritenbaugh; Lee Hullender Rubin; Rosa Schnyer; Peter M Wayne; Shelly Rafferty Withers; Bian Zhao-Xiang; Jeanette Young; Brian M Berman
Journal:  Trials       Date:  2014-05-13       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.